HYDERABAD: The Coalition for Epidemic Preparedness Innovations (CEPI) will fund a consortium comprising the Hyderabad-based Bharat Biotech and International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine.
The CEPI will provide funds upto $14.1 million to the consortium, for the manufacturing of vaccine and clinical development of a two-dose live-inactivated vaccine against Chikungunya. In addition, the consortium will be supported with a grant of upto $2 million by the Indian government’s Ind-CEPI initiative.